Literature DB >> 15752541

Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat.

A M Baker1, D C Batchelor, G B Thomas, J Y Wen, M Rafiee, H Lin, J Guan.   

Abstract

Insulin-like growth factor-I is a neurotrophic factor and can prevent neurons from ischemic brain injury. However, the large molecular weight and metabolic effects can be problematic in its central delivery. Glycine-proline-glutamate (GPE) is the N-terminal tripeptide of insulin-like growth factor-I, which is naturally cleaved in the plasma and brain tissues. GPE reduces neuronal loss from hypoxic-ischemic brain injury following central administration. Central penetration and the stability of GPE in the plasma and central nervous system were examined in rats using radioimmunoassay and HPLC. GPE was rapidly metabolised in the plasma (8 min) after intraperitoneal administration. Despite having a short half-life in plasma, GPE was detected in the cerebrospinal fluid up to 40 min after intraperitoneal administration. With present of peptidase inhibitors, GPE existed in the brain tissue up to 3 h after intracerebroventricular administration, suggesting a role for peptolysis in its stability. The endopeptidase inhibitors 4- (2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) reduced GPE metabolism in the brain tissue while acid peptidase inhibitor pepstatin-A decreased GPE metabolism in the plasma. GPE reduced neuronal loss in the CA1-2 sub-region of the hippocampus given (intraperitoneally) after 30 min of hypoxic-ischemic injury in adult rats, further suggested the effectiveness of GPE central uptake. These results indicated that GPE crosses the blood-CSF and the functional CSF-brain barriers. The longer half-life of GPE in the CNS may be due to its unique enzymatic stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752541     DOI: 10.1016/j.npep.2004.11.001

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  12 in total

Review 1.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

2.  Glutamate-related gene expression changes with age in the mouse auditory midbrain.

Authors:  Sherif F Tadros; Mary D'Souza; Martha L Zettel; Xiaoxia Zhu; Nicole C Waxmonsky; Robert D Frisina
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

3.  Regulatory effects of insulin-like growth factor-1 on the expression of sensory neuropeptide mRNAs in cultured dorsal root ganglion neurons with excitotoxicity induced by glutamate.

Authors:  Hui-Cui Gong; Xiang-Dong Yang; Zhen Liu; Zi-Ying Xing; Huai-Jing Wang; Zhen-Zhong Li
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

4.  NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome.

Authors:  Robert M J Deacon; Larry Glass; Mike Snape; Michael J Hurley; Francisco J Altimiras; Rodolfo R Biekofsky; Patricia Cogram
Journal:  Neuromolecular Med       Date:  2015-01-23       Impact factor: 3.843

5.  Insulin-like Growth Factor 1 for Healthy Spines and Healthy Minds?

Authors:  Sandhya Chandrasekaran; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2016-08-15       Impact factor: 13.382

6.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice.

Authors:  Daniela Tropea; Emanuela Giacometti; Nathan R Wilson; Caroline Beard; Cortina McCurry; Dong Dong Fu; Ruth Flannery; Rudolf Jaenisch; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

Review 7.  IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.

Authors:  Jian Guan; Peter D Gluckman
Journal:  Br J Pharmacol       Date:  2009-05-11       Impact factor: 8.739

Review 8.  Peptides Derived from Growth Factors to Treat Alzheimer's Disease.

Authors:  Suzanne Gascon; Jessica Jann; Chloé Langlois-Blais; Mélanie Plourde; Christine Lavoie; Nathalie Faucheux
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome.

Authors:  Silvia Landi; Elena Putignano; Elena Maria Boggio; Maurizio Giustetto; Tommaso Pizzorusso; Gian Michele Ratto
Journal:  Sci Rep       Date:  2011-07-25       Impact factor: 4.379

10.  Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.

Authors:  Jian Guan; Peter Gluckman; Panzao Yang; Geoff Krissansen; Xueying Sun; Yongzhi Zhou; Jingyuan Wen; Gemma Phillips; Paul R Shorten; Chris D McMahon; Graeme C Wake; Wendy H K Chan; Mark F Thomas; April Ren; Steve Moon; Dong-Xu Liu
Journal:  Sci Rep       Date:  2014-03-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.